China is the fastest-growing major healthcare market in the world, driven by burgeoning incomes, an aging population, increased life expectancy, and greater expectations about the quality of life. However, its recent reopening chaos has exposed the country's healthcare vulnerabilities and once again emphasised the importance of strong healthcare systems and the ability of the pharmaceutical industry to deliver innovative treatments and vaccines. Although President Xi Jinping reinforced the goal of prioritising the quality of healthcare and deepening ongoing healthcare reform during the party's 20th National Congress, it looks as if the world's most populous country still has a long way to go.
Government policies, innovation, investment, and shifting consumer priorities in the wake of the pandemic suggest that there is room for significant growth and substantial opportunities in this sector. From telemedicine to biotech, from AI-augmented solutions to digitalisation of the healthcare delivery systems, there are promising opportunities for global giants and scrappy local start-ups alike. At this event, industry leaders and experts will consider opportunities and challenges for this consequential sector in China.
This event is limited to senior-level executives and per invitation only. If you are not an existing member of The Economist Intelligence Corporate Network, but would like to learn how you can attend our events, please contact us.